CRBP return to pre-covid?
The stock has been above $5 most of the time.
It is only that Lenbasaum, their leading drug, has failed in one of the clinical studies, that is why the stock plummeted in Sep 2020.
Nonetheless, they have couple others ongoing studies and they may have a chance to recover to pre-covid levels.
Before the September news their ratings were Buy and Outperform at $12, $22 and even $40 levels.
Mind the fundamentals and news.
It is only that Lenbasaum, their leading drug, has failed in one of the clinical studies, that is why the stock plummeted in Sep 2020.
Nonetheless, they have couple others ongoing studies and they may have a chance to recover to pre-covid levels.
Before the September news their ratings were Buy and Outperform at $12, $22 and even $40 levels.
Mind the fundamentals and news.
Nota
Idea workedAnd it may still have some potential
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.